Display options
Cite
Grey A. Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis. 2016;8(4):119-23doi: 10.1177/1759720X16650866.
Grey, A. (2016). Intravenous zoledronate for osteoporosis: less might be more. Therapeutic advances in musculoskeletal disease, 8(4), 119-23. https://doi.org/10.1177/1759720X16650866
Grey, Andrew. "Intravenous zoledronate for osteoporosis: less might be more." Therapeutic advances in musculoskeletal disease vol. 8,4 (2016): 119-23. doi: https://doi.org/10.1177/1759720X16650866
Grey A. Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):119-23. doi: 10.1177/1759720X16650866. Epub 2016 May 19. PMID: 27493690; PMCID: PMC4959627.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Musculoskelet Dis. 2016 Aug;8(4):119-23. doi: 10.1177/1759720X16650866. Epub 2016 May 19.

Intravenous zoledronate for osteoporosis: less might be more.

Therapeutic advances in musculoskeletal disease

Andrew Grey

Affiliations

  1. Department of Medicine, University of Auckland, Private Bag 92109, Auckland, New Zealand.

PMID: 27493690 PMCID: PMC4959627 DOI: 10.1177/1759720X16650866

Abstract

Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there remain very substantial uncertainties about the optimal treatment regimen, that is, the lowest dose and/or longest dosing interval that is efficacious. Several pieces of clinical research suggest that the current recommendation for annual administration of 5 mg zoledronate might represent overtreatment. Clinical trials to clarify the optimal use of zoledronate for reduction of fracture risk should be undertaken.

Keywords: dosage; duration; fracture risk; intravenous; osteoporosis; zolendronate

References

  1. Am J Med. 2013 Jan;126(1):13-20 - PubMed
  2. Osteoporos Int. 2013 Jan;24(1):23-57 - PubMed
  3. JAMA Intern Med. 2015 Jun;175(6):913-21 - PubMed
  4. J Bone Miner Res. 2007 Oct;22(10):1479-91 - PubMed
  5. N Engl J Med. 2007 May 3;356(18):1809-22 - PubMed
  6. J Clin Endocrinol Metab. 2013 Feb;98(2):557-63 - PubMed
  7. N Engl J Med. 2012 Nov;367 (18):1714-23 - PubMed
  8. J Bone Miner Res. 2012 Feb;27(2):243-54 - PubMed
  9. JAMA. 1991 Jul 3;266(1):93-8 - PubMed
  10. BMJ. 2006 Jul 8;333(7558):60 - PubMed
  11. J Clin Endocrinol Metab. 2009 Feb;94(2):538-44 - PubMed
  12. N Engl J Med. 2002 Feb 28;346(9):653-61 - PubMed
  13. Obstet Gynecol. 2009 Nov;114(5):999-1007 - PubMed
  14. J Clin Endocrinol Metab. 2010 Sep;95(9):4380-7 - PubMed
  15. J Bone Miner Res. 2014 Jan;29(1):166-72 - PubMed
  16. Lancet. 2009 Apr 11;373(9671):1253-63 - PubMed
  17. J Bone Miner Res. 2015 May;30(5):934-44 - PubMed
  18. J Clin Endocrinol Metab. 2012 Jan;97(1):286-92 - PubMed
  19. J Clin Endocrinol Metab. 2012 Jun;97(6):1922-8 - PubMed
  20. N Engl J Med. 2009 Aug 20;361(8):818-20 - PubMed
  21. Bone. 2012 Jun;50(6):1389-93 - PubMed
  22. N Engl J Med. 2014 Sep 4;371(10):974-6 - PubMed
  23. N Engl J Med. 2007 Nov 1;357(18):1799-809 - PubMed

Publication Types